Activest Wealth Management Sells 386 Shares of Moderna, Inc. (NASDAQ:MRNA)

Activest Wealth Management lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 29.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 938 shares of the company’s stock after selling 386 shares during the quarter. Activest Wealth Management’s holdings in Moderna were worth $39,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in MRNA. Empowered Funds LLC lifted its stake in shares of Moderna by 11.2% in the 4th quarter. Empowered Funds LLC now owns 5,781 shares of the company’s stock valued at $240,000 after acquiring an additional 582 shares during the last quarter. Wilmington Savings Fund Society FSB increased its stake in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Apollon Wealth Management LLC lifted its position in Moderna by 27.6% in the fourth quarter. Apollon Wealth Management LLC now owns 6,460 shares of the company’s stock valued at $269,000 after purchasing an additional 1,396 shares during the last quarter. Quattro Financial Advisors LLC boosted its stake in shares of Moderna by 36.2% during the fourth quarter. Quattro Financial Advisors LLC now owns 84,600 shares of the company’s stock valued at $3,439,000 after purchasing an additional 22,500 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Moderna by 1.9% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 34,863 shares of the company’s stock worth $1,450,000 after purchasing an additional 657 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Down 3.0 %

Shares of NASDAQ:MRNA opened at $32.60 on Monday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $40.01 and a two-hundred day simple moving average of $57.81. Moderna, Inc. has a 12-month low of $31.94 and a 12-month high of $170.47. The stock has a market capitalization of $12.55 billion, a price-to-earnings ratio of -5.60 and a beta of 1.59.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the firm earned ($1.39) EPS. Moderna’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, research analysts anticipate that Moderna, Inc. will post -8.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Barclays lowered their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Berenberg Bank increased their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target on the stock. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. cut their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $67.26.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.